Streetbeat News

FBLG

FibroBiologics Inc

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

1.05

Mkt cap

37M

Volume

141K

High

1.05

P/E Ratio

-1.85

52-wk high

13.59

Low

1.00

Div yield

N/A

52-wk low

0.98

FibroBiologics has announced successful results for its Artificial Thymus Organoid, which demonstrated over 50 days of functionality post-transplant and the production of diverse, mature T cells. This development could have significant implications for the company's future prospects.

Portfolio Pulse from Benzinga Newsdesk

October 29, 2024 | 1:16 pm

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics (NASDAQ:FBLG) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 3:44 pm

FibroBiologics has partnered with Charles River to develop and manufacture fibroblast cell-based therapies for chronic diseases. This collaboration includes CGMP production for a diabetic foot ulcer clinical trial starting in 2025.

Portfolio Pulse from Benzinga Newsdesk

October 18, 2024 | 12:34 pm

FibreBiologics shares rose following the issuance of a European patent for their fibroblast delivery of tumor inhibitory agents.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 3:41 pm

FibroBiologics has been granted a European patent for its fibroblast delivery system of tumor inhibitory agents, potentially enhancing its market position in cancer treatment technologies.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 1:20 pm

Fibrobiologics has entered into a Master Services Agreement with Charles River Laboratories, effective from September 19, 2023, to September 19, 2029, unless terminated earlier by either party.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 8:05 pm

FibreBiologics shares rose following Maxim Group's initiation of coverage with a Buy rating and a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:38 pm

Maxim Group has initiated coverage on FibroBiologics with a Buy rating and set a price target of $12.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 12:59 pm

FibroBiologics has partnered with Southern Star Research to conduct a Phase 1/2 clinical trial in Australia for their product candidate CYWC628, aimed at treating diabetic foot ulcers.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 1:33 pm

EF Hutton analyst Jason Kolbert has reiterated a Buy rating for FibroBiologics (NASDAQ:FBLG) and maintained a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 11:56 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.